NeurAxis Stock Has 236% Upside Says GSCR Analyst, Fueled By Drug-Free IB-Stim Technology To Treat Pediatric Irritable Bowel Syndrome ($NRXS)
According to an analyst at Goldman Smallcap Research, NeurAxis Inc. shares at current levels present a compelling investment opportunity. In fact, he models for a 12-month price target of $14 a...
Source: marketscreener.com